BI0201 ADC

N/A

Report date: 2026/04/15 20:02:38

Base Information

Drug NameBI0201 ADC

Drug Alias NameBI0201 antibody drug conjugate(Protheragen)BI0201BI-0201

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionAnti-Trop-2Anti-HER2

TargetsTumor-associated calcium signal transducer 2Receptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesProtheragen Inc

China Registration ClassN/A

Develop Information

Active CompaniesProtheragen Inc

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A